Remove 2002 Remove Data Remove DEA Remove Extraction
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

However, there are indications from studies done with cannabidiol-rich cannabis extracts in Israel that indicate that less side effects (46%) are achieved with a natural cannabis plant extract containing a 20:1 ratio of CBD to THC. The CBD-rich extract group had a lower effective dose on average, 6.1

article thumbnail

Cannabis Trends of 2022

Kind Meds (Cannabis Education Blog)

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.

article thumbnail

Further Consideration of the STATES Act

Cannabis Law Report

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2, 2002 , 116 Stat. ii) 5 kilograms or more of a mixture or substance containing a detectable amount of—. .

Banking 45